Driving the Future of Investment in the Life Sciences

In another Road to 2021 interview at the Glasgow Science Centre, EOS Advisory Partner Mark Beaumont discusses the pandemic’s impact on life science investment.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

EOS Advisory

Eos are specialists in deep science, engineering and technology, taking businesses from start-up and spinout stage, through to Series A and beyond.  We back ventures that have global potential, protectable IP, a clear commercial strategy, and a management team that we can have a significant relationship with for what is typically a 5-8 year investment journey. Our approach is very selective and hands-on.

We only work with companies that are strongly motivated by the global challenges they are addressing, as well as their financial growth. 

Q: